H.R. 10628 · 119th Congress · Health

Biosimilars Access and Affordability Act

In committee1.8k words Introduced Sep 28, 2026 · Latest action Sep 28, 2026

How far it has goneStage 2 of 6
  1. IntroducedSep 28, 2026 Done
  2. CommitteeReferred to 2 committees Current stage
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

No CRS summary yet; one usually follows within a few weeks of introduction.

Who lobbies on it

4 organizations, more than 90% of House bills · 7 filings · Q3 2026

These 4 organizations’ PACs gave $169K to 12 of the 12 members sponsoring or cosponsoring H.R. 10628 in the 2025–26 election cycle.

See who got it, from which PACs, and how they compare to the rest of the House → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Pharmaceutical Research and Manufacturers of America 1 of 1 quarter
    “H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 10628: Biosimilars Access and Affordability Act S. 5571: Biosimilars Access and Affordability Act Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Part D…”

    $26.6M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  2. Merck & Co., Inc 1 of 1 quarter
    “Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.”

    $8.8M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  3. Amgen Inc 1 of 1 quarter
    “…HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act”

    $8.2M lobbying spend in 2026 to date, all issuesQ3 2026 filing

1 more organization, every filingPROUpgrade

Organizations that named H.R. 10628 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Sep 28, 2026Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  2. Sep 28, 2026Introduced in House